Addressing the emergence pediatric vaccination concerns: Recommendations from Canadian policy analysis

Canadian Journal of Public Health

Volumn 97, Issue 2, 2006, Pages 139-141

  Wilson, Kumanan ^a,b,g   Barakat, Meredith ^a   Mills, Edward ^c,d   Ritvo, Paul ^b   Boon, Heather ^b   Vohra, Sunita ^e   Jadad, Alejandro R ^f   McGeer, Allison ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Adverse events; Pediatric; Policy; Risk; Vaccination

Indexed keywords

VACCINE;

ARTICLE; CANADA; CHILD; CHILD CARE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HUMAN RELATION; IMMUNIZATION; PARENTAL ATTITUDE; PEDIATRICS; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 33645774370     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405334     Document Type: Article

References (17)

1. Bedford H, Elliman D. Concerns about immunisation. BMJ 2000;320:240-43.
2. Gust DA, Strine TW, Maurice E, Smith P, Yusuf H, Wilkinson M, et al. Underimmunization among children: Effects of vaccine safety concerns on immunization status. Pediatrics 2004;114(1):e16-22.
3. Public Health Agency of Canada. Rubella: Ontario. Infectious Diseases News Brief 2005.
4. Ritvo P, Irvine J, Klar N, Wilson K, Brown L, Bremner KE, et al. A Canadian national survey of attitudes and knowledge regarding preventive vaccines. J Immune Based Ther Vaccines 2003;1(1):3.
5. Ward L. Minister outlines steps to boost image of MMR jabs. The Guardian February 21, 2002.
6. Sabatier P. Knowledge, policy-oriented learning, and policy change. An advocacy coalition framework. Knowledge: Creation, Diffusion, Utilization 1987;8:649-92.
7. Plotkin SA. Lessons learned concerning vaccine safety. Vaccine 2001;20(Suppl 1):S16-9; discussion S1.
8. Fritzell B. Detection of adverse events: What are the current sensitivity limits during clinical development? Vaccine 2001;20(Suppl 1):S47-S48.
9. Keller-Stanislawski B. Feasibility of improving safety beyond certain limits in clinical trials. Vaccine 2001;20 Suppl 1:45-46.
10. Chen RT, DeStefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and controversies in immunization safety. Infect Dis Clin North Am 2001;15(1):21-39, viii.
11. Scheifele DW, Halperin SA. Immunization Monitoring Program, Active: A model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 2003;14(3):213-19.
12. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, et al. Vaccine Safety Datalink project: A new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997;99(6):765-73.
13. Andrews NJ. Statistical assessment of the association between vaccination and rare adverse events post-licensure. Vaccine 2001;20(Suppl 1):S49-53; discussion S45-48.
14. In support of a compensation plan for vaccine-associated injuries. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. CMAJ 1986;135(7):747-49.
15. Ridgway D. No-fault vaccine insurance: Lessons from the National Vaccine Injury Compensation Program. J Health Polit Policy Law 1999;24(1):59-90.
16. National Advisory Committee on Immunization. Supplementary statement for the 2002-2003 influenza season: Update on oculo-respiratory syndrome in association with influenza vaccination. Can Commun Dis Rep 2002;28:ACS-6.
17. F/P/T Advisory Committee on Population Health and Health Security (ACPHHS). National Immunization Strategy: Final Report 2003: Public Health Agency of Canada, 2003.